Analysts question BSX's prediction of new growth in 2013; Smith & Nephew's sales plunge;

 @FierceMedDev: St. Jude announced it is cutting 500 more jobs in through its restructuring plan. 8-K | Follow @FierceMedDev

 @MarkHFierce: Taiwan wants to get on the medical device bandwagon and has plans to jumpstart its local industry. News | Follow @MarkHFierce

 @DamianFierce: Ex-Stryker CEO Stephen MacMillan has landed on his feet after the public breakup, taking the reins at sBioMed. More | Follow @DamianFierce

> Echoing his predecessor, new Boston Scientific ($BSX) CEO Michael Mahoney told Bloomberg that he expects the company to return to revenue growth again 2013, though analysts disagree. Story

> Zimmer ($ZMH) stopped selling its metal Durom hip implant in Australia, blaming high revision rates. Story

> ConforMIS, a Massachusetts orthopedic implant maker, has moved to larger headquarters and is ramping up its manufacturing capacity. Item

> Smith & Nephew ($SNN) reported a 7.8% sales decline last quarter, the lowest numbers in 7 years. News

> Thoratec ($THOR) increased its full-year revenue guidance after bringing in $24.3 million in profits last quarter, a 32% increase over the previous year. Release

> Enzo Biochem won its patent suit against Life Technologies ($LIFE), and a jury awarded the company $48.6 million. More

Biotech News

 @FierceBiotech: Roche, pharma slice and dice DNA data to exploit cancer weaknesses. Story | Follow @FierceBiotech

 @JohnCFierce: Set some new traffic records for Fierce in Oct. 670K web visits, about a half million uniques, 1.6M page views. Biotech up to 104k subs. | Follow @JohnCFierce

 @RyanMFierce: Any idea what uniQure's gene therapy should cost? Here's our report on approval in EU. More | Follow @RyanMFierce

> U.K. public/private finance group pumps $300M into drug research. Story

> European Commission stamps approval on first gene therapy for rare disease. News

Pharma News

@FiercePharma: ICYMI yesterday: Top 15 drug patent losses for 2013. The patent cliff isn't over. Report | Follow @FiercePharma

> U.K. finally approves Roche's Zelboraf and BMS' Yervoy. Article

> J&J settles a boatload of Levaquin cases. News

> After Wellbutrin fiasco, FDA takes a look at generic equivalence. Story